[144] ORACLE CORP SEC Filing

Rhea-AI Filing Summary

This Form 144 shows a proposed sale of 19,758 common shares of Oracle Corporation (ORCL) through Fidelity Brokerage Services LLC on the 10/10/2025. The filing lists an $5,927,400.00 aggregate market value and reports 2,841,714,000 shares outstanding. The securities were acquired by restricted stock vesting as compensation on 09/15/2024 (13,615 shares), 09/15/2025 (3,483), and 09/19/2025 (2,660). No sales in the past three months are reported. The signer certifies they are not aware of undisclosed material adverse information and, if applicable, notes any Rule 10b5-1 trading plan adoption date.

Insights

Insider Transactions Analyst

Insider plans routine sale of vested restricted stock worth $5.93M.

The filing reports a proposed sale of 19,758 shares acquired through restricted stock vesting on 09/15/2024, 09/15/2025, and 09/19/2025

Because the shares were granted as compensation, the sale appears to be a liquidity event by the holder rather than a change in company fundamentals. Monitor whether the sale is executed on 10/10/2025 and whether it follows an internal trading plan such as Rule 10b5-1.

Corporate Governance Specialist

Disclosure aligns with Rule 144 requirements and includes standard no‑material‑nonpublic‑info certification.

The form lists broker, share counts, acquisition dates, and payment nature (compensation), fulfilling required fields for a Rule 144 notice. The filer also affirms not knowing undisclosed material adverse information, a common certification to limit insider trading risk.

Investors may note there were no reported sales in the prior three months; if a trading plan was relied upon, the plan adoption date should be included to clarify safe‑harbor status before execution.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	19758	5927400.00	2841714000	10/10/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/15/2024	Restricted Stock Vesting	Issuer			13615	09/15/2024	Compensation
Common	09/15/2025	Restricted Stock Vesting	Issuer			3483	09/15/2025	Compensation
Common	09/19/2025	Restricted Stock Vesting	Issuer			2660	09/19/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the ORCL Form 144 announce?

It announces a proposed sale of 19,758 common shares by an insider through Fidelity on 10/10/2025 with an aggregate market value of $5,927,400.00.

How were the shares being sold acquired?

The shares were acquired via restricted stock vesting as compensation on 09/15/2024 (13,615 shares), 09/15/2025 (3,483 shares), and 09/19/2025 (2,660 shares).

Does the filing report any securities sold in the past three months?

No. The filing states Nothing to Report for securities sold during the past three months.

Which broker and exchange are listed for the sale?

The broker is Fidelity Brokerage Services LLC and the exchange named is the NYSE.

What certification does the filer make about material nonpublic information?

By signing, the person represents they do not know any material adverse information about the issuer that has not been publicly disclosed.